HHS Override of FDA’s Plan B Review Could Signal Precedent, Hurts FDA’s Predictability Push

Drug Industry Daily
HHS Secretary Kathleen Sebelius’ decision to override a favorable review by CDER on OTC sales of Teva’s Plan B contraceptive could be a precedent-setting move that has put the FDA in uncomfortable political crosshairs amid its push to improve regulatory science and predictability.

To View This Article:


Subscribe To Drug Industry Daily